Abstract
Spectrophotometric quantification of direct factor xa inhibitor, rivaroxaban, in raw and tablet dosage form
Highlights
Rivaroxaban (RXN), chemically known as (S)-5-ChlorN-{2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5ylmethyl}thiophen-2-carbamide
RXN is a novel, oral, direct Factor Xa inhibitor approved for the management of deep vein thrombosis and pulmonary embolism [1,2,3]
The nominal content of RXN in the tablet was calculated from the corresponding calibration curve or regression equation
Summary
Rivaroxaban (RXN), chemically known as (S)-5-ChlorN-{2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5ylmethyl}thiophen-2-carbamide. A variety of analytical methods have been proposed for the estimation of RXN in bulk, pharmaceutical dosage form and biological fluids. They include factor Xa specific chromogenic substrate assay [7], anti-Factor Xa chromogenic assay [8,9,10], prothrombin time assay [11], HPLC-MS/MS [12,13,14], HPTLC [15,16], HPLC [16,17,18,19,20,21,22,23,24,25,26] and UPLC [27]. The analysis of different compounds/drugs either in pharmaceuticals/biological samples was performed after derivatization with NBD followed by measuring the resulted product by means of spectrophotometry [33,34,35,36,37,38] and spectrofluorimetry [39,40].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
